Dec 23, 2021 / 01:00PM GMT
Operator
Good morning and good afternoon, and welcome to the Leqvio FDA Approval Investor Call. (Operator Instructions) and the conference is being recorded.
(Operator Instructions)
A recording of the conference call, including the Q&A session, are available on our website shortly after the call ends.
(Operator Instructions)
With that, I would like to hand over to Samir Shah, Global Head, Investor Relations. Please go ahead.
Samir Shah - Novartis AG - Global Head of IR
Thank you very much, and thank you to all of you who are participating in this call. And it's good afternoon for the people in Europe, and good morning for the people in the U.S. Very pleased to hold -- host this particular call with you. With us, we have Marie-France Tschudin, who is the President of Novartis Pharmaceuticals; we also have David Soergel, who is the Global Head of Drug Development for cardiovascular and metabolism; and we have Victor Bulto, who is the Head of Novartis Pharmaceuticals in the U.S.
Before we start, I just wanted to read
Novartis AG Leqvio® FDA Approval Investor Call Transcript
Feb 11, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers